Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study
Go back to Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.06 +0.22 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.84 | 52 Week High | $77.12 | |||
| Open | $62.71 | 52 Week Low | $49.03 | |||
| Day High | $63.07 | P/E | 40.95 | |||
| Day Low | $62.19 | EPS | $1.54 | |||
| Volume | 36,848,550 | |||||
